

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/190622 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) *A61P 19/08* (2006.01)
A61K 39/00 (2006.01) *A61P 19/00* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/083194

(22) International Filing Date:

26 March 2021 (26.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/000,566 27 March 2020 (27.03.2020) US

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: BIOSION INC. [CN/CN]; 5th Floor, Building D, 3-1 Zhongdan Unit, South Longshan Road, Jiangbei New District, Nanjing, Jiangsu 210061 (CN).

(72) Inventors: CHEN, Mingjiu; 5th Floor, Building D, 3-1 Zhongdan Unit, South Longshan Road, Jiangbei New District, Nanjing, Jiangsu 210061 (CN). XIA, Shukai; 5th Floor, Building D, 3-1 Zhongdan Unit, South Longshan Road, Jiangbei New District, Nanjing, Jiangsu 210061 (CN).

(74) Agent: CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE; 704, Block B, Xinyu Commercial Building, 90 Guangqumen Inner Street, Dongcheng District, Beijing 100062 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODIES BINDING SIGLEC15 AND USES THEREOF

(57) Abstract: Provided herein is an isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. Also provided is a nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof. Further provided is an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.

WO 2021/190622 A1